Barclays’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Barclays’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-860	Closed	-$1K	–	7284
2016 Q4	$1K	Hold	860	–	–	﹤0.01%	6565
2016 Q3	$3K	Sell	860 -30	-3%	-$113	﹤0.01%	6201
2016 Q2	$4K	Buy	+890	New	+$4.02K	﹤0.01%	5841
2016 Q1	–	Sell	-3,280	Closed	-$33K	–	6891
2015 Q4	$33K	Sell	3,280 -580	-15%	-$13.8K	﹤0.01%	5001
2015 Q3	$77K	Sell	3,860 -2,050	-35%	-$70.2K	﹤0.01%	4783
2015 Q2	$236K	Sell	5,910 -1,190	-17%	-$71.1K	﹤0.01%	4040
2015 Q1	$497K	Sell	7,100 -3,450	-33%	-$214K	﹤0.01%	3615
2014 Q4	$633K	Buy	10,550 +1,590	+18%	+$79.9K	﹤0.01%	3636
2014 Q3	$358K	Buy	8,960 +1,920	+27%	+$103K	﹤0.01%	4247
2014 Q2	$422K	Sell	7,040 -2,430	-26%	-$141K	﹤0.01%	4154
2014 Q1	$568K	Buy	9,470 +3,070	+48%	+$208K	﹤0.01%	3828
2013 Q4	$320K	Sell	6,400 -7,040	-52%	-$396K	﹤0.01%	4541
2013 Q3	$806K	Buy	13,440 +2,350	+21%	+$159K	﹤0.01%	3589
2013 Q2	$649K	Buy	+11,090	New	+$682K	﹤0.01%	3909

Other funds holding OREX

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Barclays's OREX Position: Q2 2018 in Review

Barclays sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2018, closing a stake of 5 shares.

Barclays first reported a position in OREX in Q2 2013 and held it in 19 quarters. The position peaked at $1.07M in Q2 2014. 4 funds tracked by Wall St. Rank hold OREX as of Q2 2018.

Barclays reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Barclays sold 5 Orexigen Therapeutics, Inc. shares in Q2 2018.
Barclays first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
Barclays's Orexigen Therapeutics, Inc. position peaked at $1.07M in Q2 2014.
4 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2018.

Based on Barclays's 13F filing for Q2 2018, filed 14 Aug 2018.